A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
This study has been completed.
Sponsor:
Isis Pharmaceuticals
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002187
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: December 1998
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
| Condition | Intervention |
|---|---|
|
Cytomegalovirus Retinitis HIV Infections |
Drug: Fomivirsen sodium |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Primary Purpose: Treatment |
| Official Title: | A Randomized Comparison of Two Dosage Schedules of Intravitreal ISIS 2922 for Patients With Advanced Cytomegalovirus Retinitis |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
MedlinePlus related topics:
HIV/AIDS
U.S. FDA Resources
Further study details as provided by NIH AIDS Clinical Trials Information Service:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria
Concurrent Medication:
Allowed:
- Oral ganciclovir.
- Leukocyte growth factors (GM-CSF and G-CSF) for patients with febrile neutropenia.
Patients must have:
- Documented AIDS.
- Clinical diagnosis of advanced CMV retinitis in 1 or both eyes.
- >= 2 previous induction courses with anti-CMV retinitis therapy licensed by a regulatory agency.
- > 25% retinal involvement with CMV retinitis.
- Baseline CMV retinitis lesions which have leading edges > 1000 micrograms from the macula or optic disk.
Prior Medication:
Required:
- >= 2 previous induction courses with anti-CMV retinitis therapy licensed by a regulatory agency.
Allowed:
- All anti-CMV therapies other than ganciclovir must be discontinued no less than 2 days prior to entry.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
- External ocular infection in the eye to be treated.
- Other herpetic infections of the retina, toxoplasma, retinochoroiditis, or other disease of the fundus that would preclude assessment of CMV retinitis in the eye to be treated.
- Ocular conditions that will obstruct visualization of the posterior ocular structures on the eye to be treated.
- Retinal detachment in the eye to be treated.
- Ganciclovir implant in the eye to be treated.
- Known or suspected allergy to phosphorothioate oligonucleotides or intolerance of ISIS 2922.
- Silicone oil in the eye to be treated.
- Pseudoretinitis pigmentosa.
- Syphilis.
Patients with the following prior conditions are excluded:
- History of surgery to correct retinal detachment in the eye to be treated.
History of syphilis.
1. Systemic anti-CMV therapies other than oral ganciclovir.
- Mellaril, Stelazine, chlorpromazine and clofazimine.
- Combination use of ethambutol and fluconazole.
- Investigational medications and/or procedures for the treatment of CMV retinitis in the eye to be treated.
- Ganciclovir implant delivery device in the eye to be treated.
- Ganciclovir other than oral.
- Foscarnet.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002187
Locations
| United States, California | |
| Retina - Vitreous Associates Med Group | |
| Los Angeles, California, United States, 90017 | |
| Community Eye Med Group | |
| Pasadena, California, United States, 911052536 | |
| Dr Jacob Lalezari | |
| San Francisco, California, United States, 94115 | |
| Univ of California San Francisco / SF Gen Hosp | |
| San Francisco, California, United States, 94110 | |
| United States, District of Columbia | |
| Dr Alan Palestine | |
| Washington, District of Columbia, United States, 20006 | |
| United States, Florida | |
| Dr Julio Perez | |
| Fort Lauderdale, Florida, United States, 33060 | |
| United States, Georgia | |
| Georgia Retina | |
| Atlanta, Georgia, United States, 30327 | |
| United States, Illinois | |
| Univ of Illinois | |
| Chicago, Illinois, United States, 60612 | |
| Chicago Ctr for Clinical Research | |
| Chicago, Illinois, United States, 60610 | |
| United States, Indiana | |
| Indiana Univ Med Ctr | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, New York | |
| New York Univ Med Ctr | |
| New York, New York, United States, 10016 | |
| Vitreo - Retinal Consultants | |
| New York, New York, United States, 10028 | |
| United States, North Carolina | |
| Charlotte Eye Ear Nose & Throat Association | |
| Charlotte, North Carolina, United States, 28204 | |
| Duke Univ | |
| Durham, North Carolina, United States, 27710 | |
| United States, Pennsylvania | |
| Hahnemann Univ Hosp | |
| Philadelphia, Pennsylvania, United States, 191021192 | |
| United States, Texas | |
| Baylor College of Medicine | |
| Houston, Texas, United States, 77030 | |
| United States, Washington | |
| Novum Inc | |
| Seattle, Washington, United States, 98104 | |
Sponsors and Collaborators
Isis Pharmaceuticals
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00002187 History of Changes |
| Other Study ID Numbers: | 251D, ISIS 2922-CS9 |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by NIH AIDS Clinical Trials Information Service:
|
AIDS-Related Opportunistic Infections Antiviral Agents Drug Administration Schedule |
Cytomegalovirus Retinitis fomivirsen Vitreous Body |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Retinitis Cytomegalovirus Retinitis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
Retinal Diseases Eye Diseases Cytomegalovirus Infections Herpesviridae Infections DNA Virus Infections Eye Infections, Viral Eye Infections Fomivirsen Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013